By signing the third licensing pact with a period of just seven days, pharmaceutical company, Glenmark Glenmark Pharmaceuticals Ltd., has made a hatrick.

This third deal has been signed between Glenmark and US unit of Taro Pharmaceutical Industries. It is going to deal in the branded product category.

A statement said that Glenmark's generic unit, Glenmark Generic will be making a US FDA approved drug for Taro. It will in return get milestone payments and also royalty on sales.

Thus, it will need to make a drug whose formula has already been approved and all it needs to do is wait for it to sell well and thus get the share out of it.

However, no financial detail of the deal was revealed.

But pharmaceutical analysts and experts believe that a good amount of money is going to be involved in this deal since the whole thing deals with a branded product.

Also, they believe, the royalty payments that Glenmark will have is going to be substantial.

Till now, Glenmark has signed two more agreements with France's Sanofi-Aventis and U. S.-based Par Pharmaceutical.